RAF1 and acute myeloid leukemia: These data show that pan-RAF inhibition by LY3009120 potentiates the effect of Ara-C on AML cells, and the combination of these drugs abrogates the protective effect of bone marrow-derived MSC and overcomes MSC-mediated chemoresistance.